News articles about MYOS RENS Technology (NASDAQ:MYOS) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0893408951181 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

MYOS RENS Technology (NASDAQ:MYOS) opened at $1.29 on Wednesday. MYOS RENS Technology has a one year low of $1.02 and a one year high of $6.98.

MYOS RENS Technology (NASDAQ:MYOS) last posted its earnings results on Tuesday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. MYOS RENS Technology had a negative net margin of 941.41% and a negative return on equity of 71.14%. The firm had revenue of $0.16 million during the quarter.

Separately, ValuEngine upgraded shares of MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 6th.

In related news, CEO Joseph Mannello purchased 25,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was acquired at an average price of $1.31 per share, with a total value of $32,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 203,560 shares in the company, valued at approximately $266,663.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 58.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Insider Buying and Selling by Quarter for MYOS RENS Technology (NASDAQ:MYOS)

Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.